<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Pharmacogenomics</journal-id>
<journal-id journal-id-type="iso-abbrev">Pharmacogenomics</journal-id>
<journal-id journal-id-type="publisher-id">PGS</journal-id>
<journal-title-group>
<journal-title>Pharmacogenomics</journal-title>
</journal-title-group>
<issn pub-type="ppub">1462-2416</issn>
<issn pub-type="epub">1744-8042</issn>
<publisher>
<publisher-name>Future Medicine Ltd</publisher-name>
<publisher-loc>London, UK</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">31250731</article-id>
<article-id pub-id-type="pmc">6912848</article-id>
<article-id pub-id-type="doi">10.2217/pgs-2019-0015</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Review</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>The <italic>ANKS1B</italic> gene and its associated phenotypes: focus on CNS drug response</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Younis</surname>
<given-names>Rabha M</given-names>
</name>
<xref ref-type="aff" rid="AFF1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Taylor</surname>
<given-names>Rachel M</given-names>
</name>
<xref ref-type="aff" rid="AFF2">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id authenticated="false" contrib-id-type="orcid">https://orcid.org/0000-0003-4670-759X</contrib-id>
<name>
<surname>Beardsley</surname>
<given-names>Patrick M</given-names>
</name>
<xref ref-type="aff" rid="AFF3">
<sup>3</sup>
</xref>
<xref ref-type="aff" rid="AFF4">
<sup>4</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id authenticated="false" contrib-id-type="orcid">https://orcid.org/0000-0002-3628-2447</contrib-id>
<name>
<surname>McClay</surname>
<given-names>Joseph L</given-names>
</name>
<xref ref-type="corresp" rid="COR1">*</xref>
<xref ref-type="aff" rid="AFF1">
<sup>1</sup>
</xref>
</contrib>
<aff id="AFF1"><label>1</label>Department of Pharmacotherapy &amp; Outcomes Science, Virginia Commonwealth University School of Pharmacy, Richmond, VA 23298, USA</aff>
<aff id="AFF2"><label>2</label>Center for Military Psychiatry &amp; Neuroscience, Walter Reed Army Institute of Research, Silver Spring, MA 20910, USA</aff>
<aff id="AFF3"><label>3</label>Department of Pharmacology &amp; Toxicology, Virginia Commonwealth University School of Medicine, Richmond, VA 23298, USA</aff>
<aff id="AFF4"><label>4</label>Center for Biomarker Research &amp; Personalized Medicine, Virginia Commonwealth University, Richmond, VA 23298, USA</aff>
</contrib-group>
<author-notes>
<corresp id="COR1"><label>*</label>Author for correspondence: Tel.: <phone>+1 804 828 3428</phone>; <email xlink:href="mailto:jlmcclay@vcu.edu">jlmcclay@vcu.edu</email></corresp>
<fn fn-type="COI-statement">
<p>
<bold>Financial &amp; competing interests disclosure</bold>
</p>
<p>RM Younis was funded through a graduate studentship from Virginia Commonwealth University (VCU) School of Pharmacy and this review was completed in partial fulfillment of the doctoral requirements in Pharmaceutical Sciences at VCU. This work was funded through a pilot award from the Endowment Fund of the Wright Center for Clinical and Translational Research at VCU and UL1TR000058 from the National Center for Advancing Translational Sciences. JL McClay was partially supported by National Institute of Mental Health grant R56MH107879. PM Beardsley was supported by NIDA N01DA-14-8917, NIDA N01DA-17-8932 and DOJ D-17-OD-0092. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.</p>
<p>No writing assistance was utilized in the production of this manuscript.</p>
</fn>
</author-notes>
<pub-date date-type="pub" publication-format="electronic">
<day>28</day>
<month>6</month>
<year>2019</year>
</pub-date>
<pub-date date-type="pub" publication-format="print">
<month>6</month>
<year>2019</year>
</pub-date>
<volume>20</volume>
<issue>9</issue>
<fpage>669</fpage>
<lpage>684</lpage>
<history>
<date date-type="received">
<day>09</day>
<month>2</month>
<year>2019</year>
</date>
<date date-type="accepted">
<day>26</day>
<month>4</month>
<year>2019</year>
</date>
<date date-type="online">
<day>28</day>
<month>6</month>
<year>2019</year>
</date>
</history>
<permissions>
<copyright-statement>© 2019 Future Medicine Ltd</copyright-statement>
<copyright-year>2019</copyright-year>
</permissions>
<self-uri content-type="pdf" xlink:href="pgs-20-669.pdf" xlink:title="pdf"></self-uri>
<abstract>
<p>The <italic>ANKS1B</italic> gene was a top finding in genome-wide association studies (GWAS) of antipsychotic drug response. Subsequent GWAS findings for <italic>ANKS1B</italic> include cognitive ability, educational attainment, body mass index, response to corticosteroids and drug dependence. We review current human association evidence for <italic>ANKS1B</italic>, in addition to functional studies that include two published mouse knockouts. The several GWAS findings in humans indicate that phenotypically relevant variation is segregating at the <italic>ANKS1B</italic> locus. <italic>ANKS1B</italic> shows strong plausibility for involvement in CNS drug response because it encodes a postsynaptic effector protein that mediates long-term changes to neuronal biology. Forthcoming data from large biobanks should further delineate the role of <italic>ANKS1B</italic> in CNS drug response.</p>
</abstract>
<kwd-group kwd-group-type="author">
<title>Keywords: </title>
<kwd>antipsychotics</kwd>
<kwd>BMI</kwd>
<kwd>cognition</kwd>
<kwd>corticosteroids</kwd>
<kwd>drugs of abuse</kwd>
<kwd>glutamatergic neurotransmission</kwd>
<kwd>NMDA</kwd>
<kwd>postsynaptic density</kwd>
<kwd>serotonin</kwd>
<kwd>synapse to nucleus communication</kwd>
<kwd>synaptic plasticity</kwd>
</kwd-group>
<counts>
<page-count count="16"></page-count>
</counts>
</article-meta>
</front>
</article>
</pmc-articleset>